| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.400 | Therapeutic | group | CTD_human | Oxidative and nitrosative stress in acute ischaemic stroke. | 17270091 | 2007 | ||||
|
0.400 | Biomarker | group | CTD_human | Oxidative and nitrosative stress in acute ischaemic stroke. | 17270091 | 2007 | ||||
|
0.400 | Therapeutic | group | CTD_human | After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH Stroke Scale 0 to 1 at 3 months) at the highest three ALB doses was 81% greater than in the lower dose-tiers (relative risk [RR], 1.81; 95% confidence interval [CI], 1.11 to 2.94) and was 95% greater than in the comparable NINDS rt-PA Stroke Study cohort (RR, 1.95; 95% CI, 1.47 to 2.57). | 16809570 | 2006 | ||||
|
0.400 | Biomarker | group | CTD_human | After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH Stroke Scale 0 to 1 at 3 months) at the highest three ALB doses was 81% greater than in the lower dose-tiers (relative risk [RR], 1.81; 95% confidence interval [CI], 1.11 to 2.94) and was 95% greater than in the comparable NINDS rt-PA Stroke Study cohort (RR, 1.95; 95% CI, 1.47 to 2.57). | 16809570 | 2006 | ||||
|
0.400 | Therapeutic | group | CTD_human | High dose human serum albumin for the treatment of acute ischemic stroke: a safety study. | 16174931 | 2004 | ||||
|
0.400 | Biomarker | group | CTD_human | High dose human serum albumin for the treatment of acute ischemic stroke: a safety study. | 16174931 | 2004 | ||||
|
0.400 | Therapeutic | group | CTD_human | Risk factors for incident stroke among patients with end-stage renal disease. | 14514741 | 2003 | ||||
|
0.400 | Biomarker | group | CTD_human | Risk factors for incident stroke among patients with end-stage renal disease. | 14514741 | 2003 |